Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)

Biotechnology

Health Care

Life Sciences

Therapeutics

SYLENTIS

SYLENTIS' headquarters in Tres Cantos, Spain

Description

People (1)

Arianne Gonzalez Munoz

Jobs